Articles By Rob Wright, Chief Editor
David Lucchino’s Circuitous Route To CEO Of Frequency Therapeutics
Biopharma CEO wasn’t David Lucchino’s first, second, or even third choice as a career path. Today, though, he uses elements of his diverse background to lead his second pharma startup, Frequency Therapeutics.
What Does Travel Look Like For You In 2021?
With the annual J.P. Morgan Healthcare conference going virtual in January of 2021, Rob Wright asks readers about their business travel plans for next year, and includes anonymized thoughts on posed questions from two Life Science Leader editorial advisory board members.
From Diligence To Execution — Tim Wright’s Approach To Leading MiMedx
Tim Wright shares his due diligence approach regarding MiMedx before becoming its CEO in 2019, along with how he went about implementing his 90-day business plan that would transform the company.
What Can A Conversation On Cars Reveal About A Leader?
How many CEOs of publicly traded companies do you think can claim to driving the exact same car that they did when they first got their start? Tim Wright can.
From Food To Pharma — Andrea Pfeifer’s Trek To Cure Alzheimer’s
CEO Andrea Pfeifer talks about why, years ago, she was convinced it was time to leave her career in the food industry and cofound AC Immune, a biopharma focused on one of the most difficult areas — Alzheimer’s disease.
Leading Through Crisis
Rob Wright talks about why a virtual BIO presentation was one of the best biopharma industry educational sessions he’s ever attended.
It’s Time We Ready Americans For The COVID-19 Long Haul
Rob Wright issues a call to action to everyone connected to the biopharmaceutical industry, recommending they begin communicating the realities of developing and distributing a COVID-19 vaccine by the end of this year.
A Small Biopharma’s View Of Working With CROs
Running a clinical-stage oncology biopharma with only five employees means you quickly learn a thing or two about the value of outsourcing services. For Pamela Contag, Ph.D., cofounder and CEO of BioEclipse Therapeutics, those learnings have led to her company using five CROs for the company’s lead investigational candidate.
Aligos Therapeutics — The Next Step Of Lawrence Blatt’s Entrepreneurial Expedition
Lawrence Blatt, Ph.D., cofounder and CEO of Aligos Therapeutics, discusses the entrepreneurial journey that took him from startup, to Big Pharma, back to startup.